abstract：:In diffuse large B-cell lymphoma (DLBCL), the clinical and biological significance of concordant and discordant bone marrow (BM) involvement have not been well investigated. We evaluated 712 de novo DLBCL patients with front-line rituximab-containing treatment, including 263 patients with positive and 449 with negativ...

journal_title：Leukemia

authors： Yao Z,Deng L,Xu-Monette ZY,Manyam GC,Jain P,Tzankov A,Visco C,Bhagat G,Wang J,Dybkaer K,Tam W,Hsi ED,van Krieken JH,Ponzoni M,Ferreri AJM,Møller MB,Winter JN,Piris MA,Fayad L,Liu Y,Song Y,Orlowski RZ,Kantarjia

更新日期：2018-02-01 00:00:00

abstract：:Chromosomal rearrangements of the human MLL/KMT2A gene are associated with infant, pediatric, adult and therapy-induced acute leukemias. Here we present the data obtained from 2345 acute leukemia patients. Genomic breakpoints within the MLL gene and the involved translocation partner genes (TPGs) were determined and 1...

journal_title：Leukemia

authors： Meyer C,Burmeister T,Gröger D,Tsaur G,Fechina L,Renneville A,Sutton R,Venn NC,Emerenciano M,Pombo-de-Oliveira MS,Barbieri Blunck C,Almeida Lopes B,Zuna J,Trka J,Ballerini P,Lapillonne H,De Braekeleer M,Cazzaniga G,Cor

更新日期：2018-02-01 00:00:00

abstract：:The fms-related tyrosine kinase 3 (FLT3) receptor has been extensively studied over the past two decades with regard to oncogenic alterations that do not only serve as prognostic markers but also as therapeutic targets in acute myeloid leukemia (AML). Internal tandem duplications (ITDs) became of special interest in t...

journal_title：Leukemia

authors： Reiter K,Polzer H,Krupka C,Maiser A,Vick B,Rothenberg-Thurley M,Metzeler KH,Dörfel D,Salih HR,Jung G,Nößner E,Jeremias I,Hiddemann W,Leonhardt H,Spiekermann K,Subklewe M,Greif PA

更新日期：2018-02-01 00:00:00

abstract：:Targeted therapies are frequently combined with standard cytotoxic drugs to enhance clinical response. Targeting the B-cell lymphoma 2 (BCL-2) family of proteins is an attractive option to combat chemoresistance in leukemia. Preclinical and clinical studies indicate modest single-agent activity with selective BCL-2 in...

journal_title：Leukemia

authors： Teh TC,Nguyen NY,Moujalled DM,Segal D,Pomilio G,Rijal S,Jabbour A,Cummins K,Lackovic K,Blombery P,Thompson E,Ekert PG,Lessene G,Glaser SP,Huang DCS,Roberts AW,Guthridge MA,Wei AH

更新日期：2018-02-01 00:00:00

abstract：:The concept of arming antibodies with bioactive payloads for a site-specific therapy of cancer has gained considerable interest in recent years. However, a successful antibody-based targeting approach critically relies on the availability of a tumor-associated target that is not only preferentially expressed in the tu...

journal_title：Leukemia

authors： Angenendt L,Reuter S,Kentrup D,Benk AS,Neumann F,Hüve J,Martens AC,Schwöppe C,Kessler T,Schmidt LH,Sauer T,Brand C,Mikesch JH,Lenz G,Mesters RM,Müller-Tidow C,Hartmann W,Wardelmann E,Neri D,Berdel WE,Roesli C,Sc

更新日期：2018-02-01 00:00:00

abstract：:Chronic myelomonocytic leukemia (CMML) is a complex clonal hematological disorder classified among myelodysplastic (MDS)/myeloproliferative neoplasms. Prognosis is poor and there is a lack of effective treatments. The hypomethylating agent decitabine has shown activity against MDS and elderly acute myeloid leukemia, b...

journal_title：Leukemia

authors： Santini V,Allione B,Zini G,Gioia D,Lunghi M,Poloni A,Cilloni D,Sanna A,Masiera E,Ceccarelli M,Abdel-Wahab O,Terenzi A,Angelucci E,Finelli C,Onida F,Pelizzari A,Ferrero D,Saglio G,Figueroa M,Levis A

更新日期：2018-02-01 00:00:00

abstract：:The acquired kinase mutation JAK2V617F plays a central role in myeloproliferative neoplasms (MPNs). However, the mechanisms responsible for the malignant hematopoietic stem/progenitor cell (HSPC) expansion seen in patients with MPNs are not fully understood, limiting the effectiveness of current treatment. Endothelial...

journal_title：Leukemia

authors： Zhan H,Lin CHS,Segal Y,Kaushansky K

更新日期：2018-02-01 00:00:00

abstract：:CK2 is a ubiquitously expressed, constitutively active Ser/Thr protein kinase, which is considered the most pleiotropic protein kinase in the human kinome. Such a pleiotropy explains the involvement of CK2 in many cellular events. However, its predominant roles are stimulation of cell growth and prevention of apoptosi...

journal_title：Leukemia

authors： Buontempo F,McCubrey JA,Orsini E,Ruzzene M,Cappellini A,Lonetti A,Evangelisti C,Chiarini F,Evangelisti C,Barata JT,Martelli AM

更新日期：2018-01-01 00:00:00

abstract：:The chimeric fusion oncogene early B-cell factor 1-platelet-derived growth factor receptor-β (EBF1-PDGFRB) is a recurrent lesion observed in Philadelphia-like B-acute lymphoblastic leukemia (B-ALL) and is associated with particularly poor prognosis. While it is understood that this fusion activates tyrosine kinase sig...

journal_title：Leukemia

authors： Welsh SJ,Churchman ML,Togni M,Mullighan CG,Hagman J

更新日期：2018-01-01 00:00:00

abstract：:An increasing number of variants of unknown significance are being identified in leukemia patients with the application of deep sequencing and these include CSF3R cytoplasmic mutations. Previous studies have demonstrated oncogenic potential of certain CSF3R truncation mutations prior to internalization motifs. However...

journal_title：Leukemia

authors： Zhang H,Reister Schultz A,Luty S,Rofelty A,Su Y,Means S,Bottomly D,Wilmot B,McWeeney SK,Tyner JW

更新日期：2017-12-01 00:00:00

abstract：:This phase 1 dose-escalation study evaluated pomalidomide, bortezomib (subcutaneous (SC) or intravenous (IV)) and low-dose dexamethasone (LoDEX) in lenalidomide-refractory and proteasome inhibitor-exposed relapsed or relapsed and refractory multiple myeloma (RRMM). In 21-day cycles, patients received pomalidomide (1-4...

journal_title：Leukemia

authors： Richardson PG,Hofmeister CC,Raje NS,Siegel DS,Lonial S,Laubach J,Efebera YA,Vesole DH,Nooka AK,Rosenblatt J,Doss D,Zaki MH,Bensmaine A,Herring J,Li Y,Watkins L,Chen MS,Anderson KC

更新日期：2017-12-01 00:00:00

abstract：:Allogeneic hematopoietic stem cell transplantation (allo-SCT) represents the only curative treatment for patients with myelodysplastic syndrome (MDS), but involves non-negligible morbidity and mortality. Crucial questions in clinical decision-making include the definition of optimal timing of the procedure and the ben...

journal_title：Leukemia

authors： Della Porta MG,Jackson CH,Alessandrino EP,Rossi M,Bacigalupo A,van Lint MT,Bernardi M,Allione B,Bosi A,Guidi S,Santini V,Malcovati L,Ubezio M,Milanesi C,Todisco E,Voso MT,Musto P,Onida F,Iori AP,Cerretti R,Grillo

更新日期：2017-11-01 00:00:00

abstract：:Dipeptidylpeptidase 4 (DPP4/CD26) enzymatically cleaves select penultimate amino acids of proteins, including colony-stimulating factors (CSFs), and has been implicated in cellular regulation. To better understand the role of DPP4 regulation of hematopoiesis, we analyzed the activity of DPP4 on the surface of immature...

journal_title：Leukemia

authors： O'Leary HA,Capitano M,Cooper S,Mantel C,Boswell HS,Kapur R,Ramdas B,Chan R,Deng L,Qu CK,Broxmeyer HE

更新日期：2017-11-01 00:00:00

abstract：:ADMIRE was a multicenter, randomized-controlled, open, phase IIB superiority trial in previously untreated chronic lymphocytic leukemia. Conventional front-line therapy in fit patients is fludarabine, cyclophosphamide and rituximab (FCR). Initial evidence from non-randomized phase II trials suggested that the addition...

journal_title：Leukemia

authors： Munir T,Howard DR,McParland L,Pocock C,Rawstron AC,Hockaday A,Varghese A,Hamblin M,Bloor A,Pettitt A,Fegan C,Blundell J,Gribben JG,Phillips D,Hillmen P

更新日期：2017-10-01 00:00:00

abstract：:Neomorphic mutations in isocitrate dehydrogenase 1 (IDH1) are frequently found in several human cancer types including acute myeloid leukemia (AML) and lead to the production of high levels of the oncometabolite (R)-2-hydroxyglutarate (R-2HG). Here we report the characterization of BAY1436032, a novel pan-mutant IDH1 ...

journal_title：Leukemia

authors： Chaturvedi A,Herbst L,Pusch S,Klett L,Goparaju R,Stichel D,Kaulfuss S,Panknin O,Zimmermann K,Toschi L,Neuhaus R,Haegebarth A,Rehwinkel H,Hess-Stumpp H,Bauser M,Bochtler T,Struys EA,Sharma A,Bakkali A,Geffers R,Ara

更新日期：2017-10-01 00:00:00

abstract：:The use of darbepoetin alfa to treat anemia in patients with lower-risk myelodysplastic syndromes (MDS) was evaluated in a phase 3 trial. Eligible patients had low/intermediate-1 risk MDS, hemoglobin ⩽10 g/dl, low transfusion burden and serum erythropoietin (EPO) ⩽500 mU/ml. Patients were randomized 2:1 to receive 24 ...

journal_title：Leukemia

authors： Platzbecker U,Symeonidis A,Oliva EN,Goede JS,Delforge M,Mayer J,Slama B,Badre S,Gasal E,Mehta B,Franklin J

更新日期：2017-09-01 00:00:00

abstract：:The adult marrow hematopoietic stem cell biology has largely been based on studies of highly purified stem cells. This is unfortunate because during the stem cell purification the great bulk of stem cells are discarded. These cells are actively proliferating. The final purified stem cell is dormant and not representat...

journal_title：Leukemia

authors： Quesenberry P,Goldberg L

更新日期：2017-08-01 00:00:00

abstract：:Histone deacetylase (HDAC) inhibitors, which are approved for the treatment of cutaneous T-cell lymphoma and multiple myeloma, are undergoing evaluation in other lymphoid neoplasms. How they kill susceptible cells is incompletely understood. Here, we show that trichostatin A, romidepsin and panobinostat induce apoptos...

journal_title：Leukemia

authors： Ding H,Peterson KL,Correia C,Koh B,Schneider PA,Nowakowski GS,Kaufmann SH

更新日期：2017-07-01 00:00:00

abstract：:Immunoglobulin (IG) gene repertoire restrictions strongly support antigen selection in the pathogenesis of chronic lymphocytic leukemia (CLL). Given the emerging multifarious interactions between CLL and bystander T cells, we sought to determine whether antigen(s) are also selecting T cells in CLL. We performed a larg...

journal_title：Leukemia

authors： Vardi A,Vlachonikola E,Karypidou M,Stalika E,Bikos V,Gemenetzi K,Maramis C,Siorenta A,Anagnostopoulos A,Pospisilova S,Maglaveras N,Chouvarda I,Stamatopoulos K,Hadzidimitriou A

更新日期：2017-07-01 00:00:00

abstract：:We evaluated the impact of salvage regimens and allogeneic hematopoietic cell transplantation (allo-HCT) in acute myeloid leukemia (AML) with induction failure. Between 1993 and 2009, 3324 patients with newly diagnosed AML were enrolled in 5 prospective treatment trials of the German-Austrian AML Study Group. After fi...

journal_title：Leukemia

authors： Wattad M,Weber D,Döhner K,Krauter J,Gaidzik VI,Paschka P,Heuser M,Thol F,Kindler T,Lübbert M,Salih HR,Kündgen A,Horst HA,Brossart P,Götze K,Nachbaur D,Köhne CH,Ringhoffer M,Wulf G,Held G,Salwender H,Benner A,G

更新日期：2017-06-01 00:00:00

abstract：:Myeloproliferative neoplasm (MPN)-associated myelofibrosis is a MPN characterized by bone marrow fibrosis, cytopenias, splenomegaly and constitutional symptoms. Pomalidomide, an immune-modifying drug, is reported to improve anaemia and thrombocytopenia in some patients with MPN-associated myelofibrosis. We designed a ...

journal_title：Leukemia

authors： Schlenk RF,Stegelmann F,Reiter A,Jost E,Gattermann N,Hebart H,Waller C,Hochhaus A,Platzbecker U,Schafhausen P,Blau IW,Verbeek W,Heidel FH,Werner M,Kreipe H,Teleanu V,Benner A,Döhner H,Grießhammer M,Döhner K

更新日期：2017-04-01 00:00:00

abstract：:Myeloproliferative neoplasms with myelofibrosis (MPN-MF) demonstrate constitutive activation of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling that responds to treatment with the JAK1 and 2 kinase inhibitor (JAKi) ruxolitinib. However, MPN-MF often progresses (~20%) to secondary acu...

journal_title：Leukemia

authors： Saenz DT,Fiskus W,Manshouri T,Rajapakshe K,Krieger S,Sun B,Mill CP,DiNardo C,Pemmaraju N,Kadia T,Parmar S,Sharma S,Coarfa C,Qiu P,Verstovsek S,Bhalla KN

更新日期：2017-03-01 00:00:00

abstract：:The FMS-like tyrosine kinase-3 (FLT3) gene is the most commonly mutated gene in acute myeloid leukemia (AML), and patients carrying internal tandem duplication (ITD) mutations have a poor prognosis. Long-term inhibition of FLT3 activity in these patients has been elusive. To provide a more complete understanding of FL...

journal_title：Leukemia

authors： Wu M,Hamaker M,Li L,Small D,Duffield AS

更新日期：2017-03-01 00:00:00

abstract：:PRDM1/BLIMP-1, a master regulator of plasma-cell differentiation, is frequently inactivated in activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL) patients. Little is known about its genetic aberrations and relevant clinical implications. A large series of patients with de novo DLBCL was effectively eval...

journal_title：Leukemia

authors： Xia Y,Xu-Monette ZY,Tzankov A,Li X,Manyam GC,Murty V,Bhagat G,Zhang S,Pasqualucci L,Visco C,Dybkaer K,Chiu A,Orazi A,Zu Y,Richards KL,Hsi ED,Choi WW,van Krieken JH,Huh J,Ponzoni M,Ferreri AJ,Møller MB,Parsons

更新日期：2017-03-01 00:00:00

abstract：:The study was designed to compare clofarabine plus daunorubicin vs daunorubicin/ara-C in older patients with acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). Eight hundred and six untreated patients in the UK NCRI AML16 trial with AML/high-risk MDS (median age, 67 years; range 56-84) and norm...

journal_title：Leukemia

authors： Burnett AK,Russell NH,Hills RK,Kell J,Nielsen OJ,Dennis M,Cahalin P,Pocock C,Ali S,Burns S,Freeman S,Milligan D,Clark RE

更新日期：2017-02-01 00:00:00

abstract：:Protein kinase CK2 sustains acute myeloid leukemia cell growth, but its role in leukemia stem cells is largely unknown. Here, we discovered that the CK2 catalytic α and regulatory β subunits are consistently expressed in leukemia stem cells isolated from acute myeloid leukemia patients and cell lines. CK2 inactivation...

journal_title：Leukemia

authors： Quotti Tubi L,Canovas Nunes S,Brancalion A,Doriguzzi Breatta E,Manni S,Mandato E,Zaffino F,Macaccaro P,Carrino M,Gianesin K,Trentin L,Binotto G,Zambello R,Semenzato G,Gurrieri C,Piazza F

更新日期：2017-02-01 00:00:00

abstract：:To determine the clinical significance of minimal residual disease (MRD) in patients with prognostically relevant subtypes of childhood acute lymphoblastic leukemia (ALL), we analyzed data from 488 patients treated in St Jude Total Therapy Study XV with treatment intensity based mainly on MRD levels measured during re...

journal_title：Leukemia

authors： Pui CH,Pei D,Raimondi SC,Coustan-Smith E,Jeha S,Cheng C,Bowman WP,Sandlund JT,Ribeiro RC,Rubnitz JE,Inaba H,Gruber TA,Leung WH,Yang JJ,Downing JR,Evans WE,Relling MV,Campana D

更新日期：2017-02-01 00:00:00

abstract：:The discovery of almost identical or 'stereotyped' B-cell receptor immunoglobulins (BcR IG) among unrelated patients with chronic lymphocytic leukemia (CLL) cemented the idea of antigen selection in disease ontogeny and evolution. The systematic analysis of the stereotypy phenomenon in CLL revealed that around one-thi...

journal_title：Leukemia

authors： Stamatopoulos K,Agathangelidis A,Rosenquist R,Ghia P

更新日期：2017-02-01 00:00:00

abstract：:Post-remission treatment (PRT) in patients with cytogenetically normal (CN) acute myeloid leukemia (AML) in first complete remission (CR1) is debated. We studied 521 patients with CN-AML in CR1, for whom mutational status of NPM1 and FLT3-ITD was available, including the FLT3-ITD allelic ratio. PRT consisted of reduce...

journal_title：Leukemia

authors： Versluis J,In 't Hout FE,Devillier R,van Putten WL,Manz MG,Vekemans MC,Legdeur MC,Passweg JR,Maertens J,Kuball J,Biemond BJ,Valk PJ,van der Reijden BA,Meloni G,Schouten HC,Vellenga E,Pabst T,Willemze R,Löwenberg B,O

更新日期：2017-01-01 00:00:00

abstract：:Immunotherapy with T cell modified with gamma-retroviral or lentiviral (LV) vectors to express a chimeric antigen receptor (CAR) has shown remarkable efficacy in clinical trials. However, the potential for insertional mutagenesis and genotoxicity of viral vectors is a safety concern, and their cost and regulatory dema...

journal_title：Leukemia

authors： Monjezi R,Miskey C,Gogishvili T,Schleef M,Schmeer M,Einsele H,Ivics Z,Hudecek M

更新日期：2017-01-01 00:00:00

abstract：:Dasatinib treatment markedly increases the number of large granular lymphocytes (LGLs) in a proportion of Ph+ leukemia patients, which associates with a better prognosis. The lymphocytosis is predominantly observed in cytomegalovirus (CMV)-seropositive patients, yet detectable CMV reactivation exists only in a small f...

journal_title：Leukemia

authors： Ishiyama K,Kitawaki T,Sugimoto N,Sozu T,Anzai N,Okada M,Nohgawa M,Hatanaka K,Arima N,Ishikawa T,Tabata S,Onaka T,Oka S,Nakabo Y,Amakawa R,Matsui M,Moriguchi T,Takaori-Kondo A,Kadowaki N

更新日期：2017-01-01 00:00:00

abstract：:The nuclear export receptor, Exportin 1 (XPO1), mediates transport of growth-regulatory proteins, including tumor suppressors, and is overactive in many cancers, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML) and aggressive lymphomas. Oral selective inhibitor of nuclear export (SINE) compou...

journal_title：Leukemia

authors： Hing ZA,Fung HY,Ranganathan P,Mitchell S,El-Gamal D,Woyach JA,Williams K,Goettl VM,Smith J,Yu X,Meng X,Sun Q,Cagatay T,Lehman AM,Lucas DM,Baloglu E,Shacham S,Kauffman MG,Byrd JC,Chook YM,Garzon R,Lapalombella R

更新日期：2016-12-01 00:00:00

abstract：:The myeloproliferative neoplasms (MPNs) are characterized by hematopoietic stem/progenitor cell (HSPC) expansion and overproduction of mature blood cells. The JAK2V617F mutation is present in hematopoietic cells in a majority of patients with MPNs, but the mechanism(s) responsible for MPN stem cell expansion remain in...

journal_title：Leukemia

authors： Zhan H,Ma Y,Lin CH,Kaushansky K

更新日期：2016-12-01 00:00:00

abstract：:Outcomes for patients with multiple myeloma (MM) have improved in recent years owing to use of novel agents and high-dose therapy followed by autologous stem cell transplant (ASCT). We analyzed the outcomes of 511 consecutive patients treated with novel therapies at our institution between 2006 and 2014 to determine t...

journal_title：Leukemia

authors： Majithia N,Rajkumar SV,Lacy MQ,Buadi FK,Dispenzieri A,Gertz MA,Hayman SR,Dingli D,Kapoor P,Hwa L,Lust JA,Russell SJ,Go RS,Kyle RA,Kumar SK

更新日期：2016-11-01 00:00:00

abstract：:We describe the use and outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for multiple myeloma (MM) in Europe between January 1990 and December 2012. We identified 7333 patients, median age at allo-HSCT was 51 years (range: 18-78), of whom 4539 (62%) were males. We distinguished three groups: ...

journal_title：Leukemia

authors： Sobh M,Michallet M,Gahrton G,Iacobelli S,van Biezen A,Schönland S,Petersen E,Schaap N,Bonifazi F,Volin L,Meijer E,Niederwieser D,El Cheikh J,Tabrizi R,Fegeux N,Finke J,Bunjes D,Cornelissen J,Einsele H,Bruno B,Pott

更新日期：2016-10-01 00:00:00

abstract：:Acute myeloid leukemia (AML) is an aggressive malignancy, and development of new treatments to prolong remissions is warranted. Chimeric antigen receptor (CAR) T-cell therapies appear promising but on-target, off-tumor recognition of antigen in healthy tissues remains a concern. Here we isolated a high-affinity (HA) f...

journal_title：Leukemia

authors： Lynn RC,Feng Y,Schutsky K,Poussin M,Kalota A,Dimitrov DS,Powell DJ Jr

更新日期：2016-06-01 00:00:00

abstract：:The role of endothelial progenitor cell (EPC)-mediated vasculogenesis in hematological malignancies is not well explored. Here, we showed that EPCs are mobilized from the bone marrow (BM) to the peripheral blood at early stages of multiple myeloma (MM); and recruited to MM cell-colonized BM niches. Using EPC-defective...

journal_title：Leukemia

authors： Moschetta M,Mishima Y,Kawano Y,Manier S,Paiva B,Palomera L,Aljawai Y,Calcinotto A,Unitt C,Sahin I,Sacco A,Glavey S,Shi J,Reagan MR,Prosper F,Bellone M,Chesi M,Bergsagel LP,Vacca A,Roccaro AM,Ghobrial IM

更新日期：2016-05-01 00:00:00

abstract：:Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-a subtype of Hodgkin lymphoma (HL)-is characterized by a low content of tumor cells, the lymphocyte predominant (LP) cells. Transformation into diffuse large B-cell lymphoma (DLBCL) occurs in about 10% of patients. We performed whole-genome mutation analysis of t...

journal_title：Leukemia

authors： Hartmann S,Schuhmacher B,Rausch T,Fuller L,Döring C,Weniger M,Lollies A,Weiser C,Thurner L,Rengstl B,Brunnberg U,Vornanen M,Pfreundschuh M,Benes V,Küppers R,Newrzela S,Hansmann ML

更新日期：2016-04-01 00:00:00

abstract：:Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). Allogeneic hematopoietic stem cell transplantation (HSCT) is regarded as salvage therapy. This prospective randomized CML-study IIIA recruited 669 patients with newly diagnosed CML between July 1997 and January 2004 fro...

journal_title：Leukemia

authors： Gratwohl A,Pfirrmann M,Zander A,Kröger N,Beelen D,Novotny J,Nerl C,Scheid C,Spiekermann K,Mayer J,Sayer HG,Falge C,Bunjes D,Döhner H,Ganser A,Schmidt-Wolf I,Schwerdtfeger R,Baurmann H,Kuse R,Schmitz N,Wehmeier A,

更新日期：2016-03-01 00:00:00

abstract：:The FOXP1 (forkhead box P1) transcription factor is a marker of poor prognosis in diffuse large B-cell lymphoma (DLBCL). Here microarray analysis of FOXP1-silenced DLBCL cell lines identified differential regulation of immune response signatures and major histocompatibility complex class II (MHC II) genes as some of t...

journal_title：Leukemia

authors： Brown PJ,Wong KK,Felce SL,Lyne L,Spearman H,Soilleux EJ,Pedersen LM,Møller MB,Green TM,Gascoyne DM,Banham AH

更新日期：2016-03-01 00:00:00